Abstract:The COVID-19 pandemic, fueled by the emergence of SARS-CoV-2 Omicron variants, has raised concerns surrounding immune evasion and the effectiveness of existing vaccination strategies.1 The initial emergence of the Omicron variant BA.1 in November 2021, characterised by significant mutations in the spike glycoprotein, has led to partial evasion of previously acquired immunity from the original SARS-CoV-2 strain. Subsequently, a succession of Omicron sublineages, including BA.2, BA.5, BQ.1 and EG.5 have come to the forefront on a global scale. COVID-19 manifests a spectrum of symptoms from mild to severe, including cough, fever, dyspnoea and sometimes respiratory failure, alongside a substantial incidence of asymptomatic cases. To combat this, a diverse array of SARS-CoV-2 vaccines, including mRNA, adenovirus-based and inactivated vaccines, have been developed. Accumulating evidence suggests that administering a third dose of either an mRNA or inactivated vaccine may confer protection by reducing the severity of the symptoms and mortality.2, 3 However, the intricate immunological mechanisms behind these observations mandate comprehensive investigation. Recent studies, including our own work published in Cell,4 have emphasised the crucial role of adaptive immunity in COVID-19 vaccination. Neutralising antibody levels are a strong indicator of immune defense against symptomatic SARS-CoV-2 infection.5 Inactivated vaccines, although eliciting lower neutralising antibody levels than mRNA vaccines, provide comparable protection with a three-dose regimen.2, 3 It is reported that the protection of T-cell response induced by inactivated vaccines is characterised by a robust CD4 response, though accompanied by a weaker CD8 response.6 In our study, Omicron-infected individuals who received a third inactivated vaccine dose showed significant expansion in three effector memory CD4+ T-cell subsets: CD161hi effector memory, CD27int effector memory and Th1-like effector memory cells. This suggests that vaccination fuels the formation of long-term CD4+ T-cell memory pools, capable of responding to subsequent SARS-CoV-2 infections, including the Omicron variant. Importantly, post vaccination, especially after the third dose, CD4+ T cells tend to skew toward a Th1-type response characterised by IFN-γ secretion, rather than Th2, Th17 or TFH responses upon Omicron infection. This aligns with prior findings that both mRNA and inactivated vaccines induce a Th1-polarised response, which is likely associated with asymptomatic infection. Our results also indicate that the frequency of regulatory T cells (Tregs) and their expression of TIM-3 were increased post infection, but this effect is diminished in triple-vaccinated individuals, suggesting that the vaccination might counteract the infection-induced Treg expansion and activation, which could suppress CD4+ T-cell activation and recall. Genes associated with Treg functional stability were upregulated, while Treg proliferation genes were downregulated in the three-dose group. These findings support the notion that the enhanced number and pathogenic activation of Tregs upon Omicron infection, typically associated with delayed CD4+ T-cell activation, can be effectively curtailed by a three-dose vaccination regimen. While extensive research has predominantly focused on the adaptive immune response, particularly its humoral components in COVID-19 vaccination, the role of innate immunity has received comparatively less attention. Innate immune cells, including neutrophils, monocytes, macrophages, dendritic cells (DCs) and natural killer (NK) cells, play pivotal roles in the initial defense against viral infections, contributing to shaping the subsequent adaptive immune response. Studies report that two mRNA vaccine doses were able to strengthen the innate immune response, increasing the frequency of inflammatory intermediate monocytes and enhancing innate antiviral signatures.7 With three mRNA vaccine doses, NK cell maturation is promoted, underscoring the importance of this innate immunity response.8 In our study,4 we found that the Omicron-infected individuals displayed reduced frequencies of HLA-DRint classical monocytes (HLA-DRint−CM), HLA-DRhi classical monocytes (HLA-DRhi-CM) and non-classical monocytes (NCM) compared to healthy controls. Notably, the frequencies of HLA-DRint−CM and NCM were partially restored with a third vaccine dose. HLA-DRhi-CM and NCM frequencies correlated positively with viral replication inhibition, suggesting their role in antiviral defense. Additionally, Omicron infection decreased plasmacytoid dendritic cell (pDC) frequencies, which are partially reconstituted after the third dose. Moreover, there was a shift in the frequency of NK cell subsets, with a decrease in cytokine-secreting CD56hiCD16lo NK cells and an increase in CD56intCD16hi cytotoxic NK cells following three vaccine doses in Omicron-infected individuals. These results indicate that three doses of the inactivated vaccine promote the activation and maturation of monocytic, dendritic and NK cells. Notably, we observed negative correlations between the frequencies of HLA-DRhi-CM, NCM, pDC and the frequency of Tregs, hinting at an inverse relationship between monocytic/dendritic activation and pathogenic Treg expansion. Many studies over the past century have demonstrated that specific vaccines, especially those utilising live attenuated microorganisms like the Bacillus Calmette–Guérin (BCG) vaccine, robustly activate myelopoiesis and boost innate immune cell functionality upon pathogen challenge, a phenomenon known as 'trained immunity'.9 The mechanism of trained immunity in myeloid cells involves the remodeling of the epigenetic landscape, driven by key transcription factors such as C/EBPβ, PU.1 and interferon regulatory factors (IRFs), coupled with metabolic rewiring, which leads to enhanced killing capacity and production of cytokines and chemokines.10 While BCG-trained innate immunity was considered as a potential way to prompt protection against SARS-CoV-2, it remained unclear whether the inactivated vaccine could induce trained immunity programmes against Omicron. Our study provides evidence that a substantial portion of genes activated by vaccination in healthy individuals undergo similar changes following Omicron infection. Interestingly, most of these shared genes, including critical regulators like TREM1, C5AR1 and FOSL1, are most highly expressed in monocytes among the 26 immune cell types of peripheral blood mononuclear cells (PBMCs). This observation suggests that the essential monocytic-driven pathways, such as TREM1 upregulation upon Omicron infection, might be primed by prior vaccination-induced monocytic training in healthy individuals. Furthermore, our research reveals that trained immunity, induced by booster vaccination, predominantly stimulates monocytic activation and differentiation, rather than the suppression of monocytes typically seen in SARS-CoV-2 infection. In conclusion, the newly published work enriches our understanding of the immunomodulatory effects of inactivated virus vaccines. Our study systematically elucidates the impact of inactivated COVID-19 vaccine inoculation on the innate and adaptive immune responses in Omicron-infected subjects (Figure 1). Moreover, we uncover the intricate molecular mechanisms behind the potent antiviral effects induced by three booster doses through 'trained immunity'. This pivotal discovery is expected to provide a scientific basis for future vaccine development and immunisation strategies. S.Y wrote the manuscript. J.Z and J.Q provided important instructions and revised the manuscript. S.C critically read the manuscript. This work was supported by Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases (20dz2261100) and Cultivation Project of Shanghai Major Infectious Disease Research Base (20dz2210500). The authors declare they have no conflicts of interest. None

Abstract:During the SARS-CoV-2 pandemic, multiple variants surmounted pre-existing immune barriers, causing steady breakthrough infections in previously vaccinated individuals. Nevertheless, multiple-dose vaccinations based on the SARS-CoV-2 prototype conferred protection during Omicron challenge.1 However, the cellular mechanisms remain unresolved. In a recent study published in Cell, Yu et al. revealed that booster vaccinations may prompt innate immunity training, benefiting host defence against Omicron challenge by facilitating the differentiation of HLA-DRhi classical monocyte (HLA-DRhi-CMs) and non-classical monocytes (NCMs) from monocytes upon infection.2 Therefore, this study provided new insight into how booster vaccinations induce trained immunity against infection with SARS-CoV-2 variants. Booster vaccinations can trigger strikingly long-term immune and antibody responses before infection.3 To investigate how prior booster vaccinations based on the COVID-19 prototype modulate human immune responses during Omicron challenge, Yu et al. enrolled 122 Omicron-infected patients and 50 uninfected participants, who were either not vaccinated or pre-vaccinated with different doses of inactive vaccines based on the COVID-19 prototype. The participants were then divided into six groups, and a systemic analysis was performed on their circulating mononuclear cells and plasma cytokines using mass cytometry and Olink proteomics. First, the authors investigated the in-depth characteristics of both the lymphocytic and myeloid compartments across the six groups (cohort). In this regard, they found that levels of regulatory T cells (Tregs) and three subpopulations of CD4+-naïve T cells were elevated by Omicron infection, whereas three-dose booster vaccinations dampened these tendencies. Moreover, booster vaccinations increased the number of Th1 CD4+ T cells and Th1-like effector memory CD4+ T cells. However, prior booster vaccinations did not change the frequencies of other lymphocytic subsets, such as CD8+ T, NKT, or B cells, during infection. Thus, prior booster vaccinations may benefit the expansion of CD4+ effector T cells from CD4+-naïve T cells by curbing the increase in Tregs during Omicron infection. Innate myeloid immune cells play a key role in the acute phase of viral infection. The authors also investigated the alterations in six myeloid clusters and observed that three subsets of effector monocytes decreased significantly upon Omicron challenge, suggesting that human innate immunity was suppressed by Omicron infection. Nevertheless, booster vaccinations significantly elevated the frequencies of NCMs and HLA-DRhi-CMs (Figure 1). Importantly, they found a positive correlation among HLA-DRhi-CM, pDC, and NCM subsets, whereas Tregs were negatively correlated with these subsets. Hence, prior booster vaccinations stimulate an innate immunity activation module. Next, the authors comprehensively analyzed PBMCs by bulk mRNA-seq to gain functional and mechanistic insight. To this end, the authors compared the vaccination-induced significantly altered genes in uninfected participants with those in infected patients, and found a commonly regulated gene cluster that included TREM1 and C5AR1, two key genes involved in the regulation of monocyte activation. In the vax3-inf group, the expression levels of TREM1 and C5AR1 were significantly upregulated in the asymptomatic patients. Yu et al. also identified several top-ranked molecular pathways by GSEA. Pathways associated with the activation of monocytes and effector memory T cells were activated by prior booster vaccinations during infection, whereas immunodeficiency and myeloid-derived suppressive cell (MDSC) polarization activities were not upregulated by three-dose vaccination, suggesting that specific trained pathways involved in monocytic activation that prepare hosts against Omicron infection could originate from prior booster vaccinations. Consistently, the percentage of asymptomatic patients was the highest in the three-dose vaccination group. Moreover, it was shown that the frequencies of two subsets of effector monocytes and the percentage of asymptomatic patients were positively correlated with the key regulatory pathways that were significantly activated in the three-dose vaccination group, whereas the activity of Tregs was negatively correlated with the key regulatory pathways upregulated by booster vaccinations. These findings suggest that prior three-dose booster vaccination may prepare the host in coping with Omicron infection by promoting the activation and differentiation of trained monocytes into effector monocyte subsets (Figure 1). Plasma is an important microenvironment influencing the immune state through abundant inflammatory factors. The authors systematically evaluated 180 cytokines in the plasma across the cohort, and identified several top-ranked molecular pathways and cytokines associated with monocytic activation and Treg restraint. Accordingly, the expansion of two subsets of HLA-DRhi-CM and NCM effector monocytes was promoted in patients who had obtained prior booster vaccinations, suggesting that a plasma microenvironment that benefits monocyte activation and differentiation was induced by prior booster vaccinations (Figure 1). In conclusion, this outstanding work by Yu et al. systematically investigated the human cellular and immune responses and mechanisms modulated by prior booster vaccinations, particularly innate immunity memory, during Omicron challenge. Briefly, booster vaccinations induced a plasma microenvironment and a transcriptional signature of enhanced memory-like innate response, which was consistent with the enhanced activation and differentiation of monocytes during Omicron infection. Thus, patients who had received booster vaccinations showed increased expansion of HLA-DRhi-CMs and NCMs effector monocytes and milder symptoms (Figure 1). Most vaccines require multiple doses to elicit long-lasting immune memory protection, which has been classically attributed solely to adaptive immunity. However, recent studies have shown that human innate immunity is also equipped with adaptive characteristics after being challenged with pathogens, and can display long-term protectional changes that increase nonspecific responses to subsequent infections. This phenomenon has been described as innate immunity memory or trained immunity.4 During the COVID-19 pandemic, scientists reported a significantly enhanced innate immune response triggered by both booster BNT162b2 mRNA and SARS-CoV-2 inactivated vaccinations.2, 5 Moreover, the heterologous booster vaccinations demonstrated a better advantage in stimulating a faster and more robust humoral response than the homologous booster vaccinations did. However, both heterologous and homologous boosters can mount antibody responses persisting for over 6 months through metabolic reprogramming of B cells.3 Consistently, booster vaccinations and infection-induced hybrid immunity showed strong protection against Omicron variants.1 Recently, Yu et al. found that booster vaccinations based on wild-type SARS-CoV-2 can markedly induce innate immunity memory against Omicron challenge by enhancing the activation and differentiation of monocytes over the expansion of B, CD8+ T, and NKT cells.2 Whether a heterologous booster strategy might promote the activation and differentiation of monocytes during Omicron infection remains unclear, warranting further investigation into the durability and metabolic and epigenetic profiles of these trained monocytes. It is worth pointing out that monocytes in circulation and bone marrow undergo dynamic changes influenced by nutrition status; therefore, whether these alterations in immune cell frequencies are attributed to their migration behaviors needs to be ruled out. The ongoing SARS-CoV-2 pandemic has raised more concerns about the effectiveness of current vaccination strategies. It is well known that the host defense system is shaped by the interaction of innate and adaptive immunity, and that the innate immune response is a prelude to the activation of B cells and T cells. Optimization of vaccination strategies requires a deeper knowledge of how different vaccination strategies affect innate immune cells, because trained innate immunity might be a game-changer in booster vaccination strategies. Undoubtedly, this study by Yu et al. demonstrates that prior booster vaccinations based on prototype SARS-CoV-2 prime the innate immune system to mount a more potent response during Omicron challenge, providing valuable guidance for next-generation booster strategies against unexpected viral outbreaks. Lan Bai and Long Zhang wrote the manuscript and prepared the figure. Fangfang Zhou provided valuable discussion. All authors have read and approved the final version of the manuscript. Not applicable. The authors declare they have no conflicts of interest. Not applicable. Not applicable.

Systemic immune profiling of Omicron-infected subjects inoculated with different doses of inactivated virus vaccine

Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination

The Roles of Innate and Adaptive Immunity in Inactivated Viral Vaccination‐mediated Protection Against COVID‐19

Booster Vaccination: Host Preparation Against Omicron Challenge by Innate Immunity Training

Omicron COVID-19 Variant Outcomes and Vaccination in Non-Severe and Non-Critical Patients at Admission

Integrative proteomics and metabolomics study reveal enhanced immune responses by COVID‐19 vaccine booster shot against Omicron SARS‐CoV‐2 infection

Comprehensive Humoral and Cellular Immune Responses to SARS-CoV-2 Variants in Diverse Chinese Population

B-086 Evaluation of Long-Term Adaptive Immune Responses Specific to SARS-CoV-2: Effect of Various Vaccination and Omicron Exposure

Comparing T- and B-cell responses to COVID-19 vaccines across varied immune backgrounds

The effectiveness of booster vaccination of inactivated COVID-19 vaccines against susceptibility, infectiousness, and transmission of omicron BA.2 variant: a retrospective cohort study in Shenzhen, China

Evaluation of Long-Term Adaptive Immune Responses Specific to SARS-CoV-2: Effect of Various Vaccination and Omicron Exposure

Evaluation of Antibody Kinetics and Durability in Healthy Individuals Vaccinated with Inactivated COVID-19 Vaccine (coronavac): A Cross-Sectional and Cohort Study in Zhejiang, China

An Integrative Analysis of the Immune Features of Inactivated SARS-CoV-2 Vaccine (CoronaVac)

Increased antibody titers but induced T cell AICD and apoptosis response in COVID-19 convalescents by inactivated vaccine booster

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost

Finite immune imprinting on neutralizing antibody responses to Omicron subvariants by repeated vaccinations

SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients

Innate immune imprints in SARS-CoV-2 Omicron variant infection convalescents

Omicron breakthrough infections after triple‐dose inactivated COVID‐19 vaccination: A comprehensive analysis of antibody and T‐cell responses

Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19

Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study